Secukinumab
- PDF / 169,247 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 59 Downloads / 152 Views
1 S
Infection and lymphocytic colitis: 2 case reports In a retrospective observational cohort study of 390 patients conducted from February 2015 to 31 December 2019, 2 patients [ages and sexes not stated] were described, who developed infection (1 patient) and lymphocytic colitis (1 patient) during treatment with secukinumab for axial spondyloarthritis (axSpA) [routes, dosages, durations of treatments to reactions onsets and outcomes not stated]. The patients, who had axSpA, had previously received unspecified tumor necrosis factor inhibitor (TNFi). However, the TNFi treatment failed. Therefore, they were initiated on secukinumab. However, the patients developed infection requiring hospitalisation (1 patient) and lymphocytic colitis (1 patient). Therapy with secukinumab was discontinued in both the patients. Micheroli R, et al. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. Annals of the Rheumatic Diseases 79: 1203-1209, No. 9, Sep 2020. Available from: URL: http://doi.org/10.1136/ 803518518 annrheumdis-2019-215934
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
